Dabigatran is also contraindicated in patients who have severe renal impairment (creatinine clearance <30 mL/min); have hepatic impairment or liver disease expected to have any impact on survival; have prosthetic heart valves requiring anticoagulant treatment; or are receiving concomitant treatment with strong P-glycoprotein inhibitors [10]. Here, ABCB1 is linked to liver disorder.